ID

34714

Descripción

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist; ODM derived from: https://clinicaltrials.gov/show/NCT01381926

Link

https://clinicaltrials.gov/show/NCT01381926

Palabras clave

Versiones (1)
  1. 2019-01-24 2019-01-24 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

24 januari 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes Mellitus NCT01381926

Inglés

Eligibility Type 2 Diabetes Mellitus NCT01381926

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal women (as defined by age ≥45 years old or amenorrhea for >2years)
Descripción

Postmenopausal state | Age | Amenorrhea Duration

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0001779
UMLS CUI [3,1]
C0002453
UMLS CUI [3,2]
C0449238
type 2 dm currently not on diabetes-specific medication(s) or treated with monotherapy of metformin or a sulfonylurea. patients treated with insulin monotherapy will also be eligible if the total daily dose of insulin is ≤10units. if on a medication for diabetes prior to study entry, the medication can be discontinued for 2 weeks prior to study initiation.
Descripción

Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Absent | Metformin | Sulfonylurea | Insulin regime U/day

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C0025598
UMLS CUI [4]
C0038766
UMLS CUI [5,1]
C0557978
UMLS CUI [5,2]
C0456683
hemoglobin a1c (hba1c) of 6.5-9.0%
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of an incretin mimetic (i.e. exenatide, liraglutide), a dpp-4 inhibitor (i.e. sitagliptin, saxagliptin), a thiazolidinedione, or oral glucocorticoids in the 6 months prior to the study will not be eligible
Descripción

Incretin mimetic product | exenatide | liraglutide | Dipeptidyl-Peptidase IV Inhibitors | sitagliptin | saxagliptin | Thiazolidinediones | Glucocorticoids Oral

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1562104
UMLS CUI [2]
C0167117
UMLS CUI [3]
C1456408
UMLS CUI [4]
C1827106
UMLS CUI [5]
C1565750
UMLS CUI [6]
C1611934
UMLS CUI [7]
C1257987
UMLS CUI [8,1]
C0017710
UMLS CUI [8,2]
C1527415
known osteoporosis or patients treated with an osteoporosis-specific medication (bisphosphonate, teriparatide) or estrogen (including selective estrogen receptor modulators (serms)) or those who anticipate imminent treatment with one of these medications will be excluded from the study
Descripción

Osteoporosis | Pharmaceutical Preparations Osteoporosis Specific | Diphosphonates | Teriparatide | Estrogens | Selective Estrogen Receptor Modulators

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029456
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0029456
UMLS CUI [2,3]
C0205369
UMLS CUI [3]
C0012544
UMLS CUI [4]
C0070093
UMLS CUI [5]
C0014939
UMLS CUI [6]
C0732611
chronic kidney disease (calculated gfr <30 ml/min) or a disease known to affect bone turnover (i.e. paget disease, osteogenesis imperfecta, hiv) will be excluded from the study.
Descripción

Chronic Kidney Disease | Glomerular Filtration Rate | Disease Affecting Bone remodeling | Paget's disease | Osteogenesis Imperfecta | HIV Infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1561643
UMLS CUI [2]
C0017654
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0085268
UMLS CUI [4]
C0029401
UMLS CUI [5]
C0029434
UMLS CUI [6]
C0019693
history of pancreatitis
Descripción

Pancreatitis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030305
Volver a la parte superior de la página

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01381926

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state | Age | Amenorrhea Duration
Item
postmenopausal women (as defined by age ≥45 years old or amenorrhea for >2years)
boolean
C0232970 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0002453 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Absent | Metformin | Sulfonylurea | Insulin regime U/day
Item
type 2 dm currently not on diabetes-specific medication(s) or treated with monotherapy of metformin or a sulfonylurea. patients treated with insulin monotherapy will also be eligible if the total daily dose of insulin is ≤10units. if on a medication for diabetes prior to study entry, the medication can be discontinued for 2 weeks prior to study initiation.
boolean
C0011860 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0025598 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C0557978 (UMLS CUI [5,1])
C0456683 (UMLS CUI [5,2])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) of 6.5-9.0%
boolean
C0474680 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Incretin mimetic product | exenatide | liraglutide | Dipeptidyl-Peptidase IV Inhibitors | sitagliptin | saxagliptin | Thiazolidinediones | Glucocorticoids Oral
Item
use of an incretin mimetic (i.e. exenatide, liraglutide), a dpp-4 inhibitor (i.e. sitagliptin, saxagliptin), a thiazolidinedione, or oral glucocorticoids in the 6 months prior to the study will not be eligible
boolean
C1562104 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C1456408 (UMLS CUI [3])
C1827106 (UMLS CUI [4])
C1565750 (UMLS CUI [5])
C1611934 (UMLS CUI [6])
C1257987 (UMLS CUI [7])
C0017710 (UMLS CUI [8,1])
C1527415 (UMLS CUI [8,2])
Osteoporosis | Pharmaceutical Preparations Osteoporosis Specific | Diphosphonates | Teriparatide | Estrogens | Selective Estrogen Receptor Modulators
Item
known osteoporosis or patients treated with an osteoporosis-specific medication (bisphosphonate, teriparatide) or estrogen (including selective estrogen receptor modulators (serms)) or those who anticipate imminent treatment with one of these medications will be excluded from the study
boolean
C0029456 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0029456 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
C0012544 (UMLS CUI [3])
C0070093 (UMLS CUI [4])
C0014939 (UMLS CUI [5])
C0732611 (UMLS CUI [6])
Chronic Kidney Disease | Glomerular Filtration Rate | Disease Affecting Bone remodeling | Paget's disease | Osteogenesis Imperfecta | HIV Infection
Item
chronic kidney disease (calculated gfr <30 ml/min) or a disease known to affect bone turnover (i.e. paget disease, osteogenesis imperfecta, hiv) will be excluded from the study.
boolean
C1561643 (UMLS CUI [1])
C0017654 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0085268 (UMLS CUI [3,3])
C0029401 (UMLS CUI [4])
C0029434 (UMLS CUI [5])
C0019693 (UMLS CUI [6])
Pancreatitis
Item
history of pancreatitis
boolean
C0030305 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial